HK이노엔(195940) IR & PR 공식채널
Ir al canal en Telegram
1 648
Suscriptores
-124 horas
-17 días
-1030 días
Carga de datos en curso...
Canales Similares
Sin datos
¿Algún problema? Por favor, actualice la página o contacte a nuestro gerente de soporte.
Nube de Etiquetas
Sin datos
¿Algún problema? Por favor, actualice la página o contacte a nuestro gerente de soporte.
Menciones Entrantes y Salientes
---
---
---
---
---
---
Atraer Suscriptores
julio '26
julio '26
+10
en 1 canales
junio '26
+44
en 6 canales
Get PRO
mayo '26
+11
en 1 canales
Get PRO
abril '26
+12
en 0 canales
Get PRO
marzo '26
+3
en 0 canales
Get PRO
febrero '26
+18
en 3 canales
Get PRO
enero '26
+57
en 16 canales
Get PRO
diciembre '25
+29
en 7 canales
Get PRO
noviembre '25
+24
en 0 canales
Get PRO
octubre '25
+46
en 10 canales
Get PRO
septiembre '25
+56
en 11 canales
Get PRO
agosto '25
+72
en 4 canales
Get PRO
julio '25
+20
en 2 canales
Get PRO
junio '25
+85
en 16 canales
Get PRO
mayo '25
+36
en 2 canales
Get PRO
abril '25
+145
en 23 canales
Get PRO
marzo '25
+25
en 4 canales
Get PRO
febrero '25
+18
en 0 canales
Get PRO
enero '25
+36
en 3 canales
Get PRO
diciembre '24
+32
en 5 canales
Get PRO
noviembre '24
+67
en 13 canales
Get PRO
octubre '24
+45
en 8 canales
Get PRO
septiembre '24
+58
en 2 canales
Get PRO
agosto '24
+77
en 4 canales
Get PRO
julio '24
+63
en 7 canales
Get PRO
junio '24
+54
en 9 canales
Get PRO
mayo '24
+71
en 5 canales
Get PRO
abril '24
+55
en 1 canales
Get PRO
marzo '24
+78
en 4 canales
Get PRO
febrero '24
+20
en 1 canales
Get PRO
enero '24
+37
en 3 canales
Get PRO
diciembre '23
+54
en 12 canales
Get PRO
noviembre '23
+44
en 4 canales
Get PRO
octubre '23
+61
en 2 canales
Get PRO
septiembre '23
+797
en 0 canales
| Fecha | Crecimiento de Suscriptores | Menciones | Canales | |
| 18 julio | 0 | |||
| 17 julio | 0 | |||
| 16 julio | +1 | |||
| 15 julio | 0 | |||
| 14 julio | +1 | |||
| 13 julio | 0 | |||
| 12 julio | +2 | |||
| 11 julio | 0 | |||
| 10 julio | 0 | |||
| 09 julio | +1 | |||
| 08 julio | 0 | |||
| 07 julio | +1 | |||
| 06 julio | 0 | |||
| 05 julio | +1 | |||
| 04 julio | 0 | |||
| 03 julio | 0 | |||
| 02 julio | 0 | |||
| 01 julio | +3 |
Publicaciones del Canal
| 2 |  Sin texto... | 317 |
| 3 | iM증권_HK이노엔_잠잠하게_지나가는_시기_20260713.pdf | 319 |
| 4 |  Sin texto... | 313 |
| 5 | 다올투자증권_HK이노엔_단기_실적_노이즈_속_글로벌_모멘텀_20260713.pdf | 255 |
| 6 |  Sin texto... | 243 |
| 7 | DS투자증권_HK이노엔_2Q26_Pre_해외_모멘텀_가시화_기대_20260713.pdf | 219 |
| 8 |  Sin texto... | 223 |
| 9 | 상상인증권_HK이노엔_2분기_실적은_시장_컨센서스와_유사할_전망_20260710.pdf | 199 |
| 10 |  Sin texto... | 252 |
| 11 | 삼성증권_HK이노엔_케이캡_다음의_성장_스토리_20260710.pdf | 273 |
| 12 |  Sin texto... | 278 |
| 13 | 금일 발간된 증권사 리포트 공유드립니다.
(Sharing reports published today) | 287 |
| 14 | HK inno.N Ranked No. 1 in Sustinvest ESG Evaluation
- No. 1 among companies with assets of KRW 2 trillion or more — the 5th consecutive ranking No. 1 in its size grade
- Published the '2025 Sustainability Report'; strengthened its management system by building an ESG data platform
HK inno.N announced on July 1 that it received the highest grade (AA) in the '1H 2026 ESG Evaluation' released by ESG rating agency Sustinvest, and was ranked No. 1 among companies with assets of KRW 2 trillion or more.
Sustinvest is one of Korea’s leading ESG rating agencies, conducting ESG evaluations of domestic companies in the first and second half of each year. The 1H 2026 evaluation covered 1,305 Korean companies.
According to the results, HK inno.N ranked No. 1 in the KRW 2 trillion-plus asset group within the “ESG Best Companies 100” — the 100 listed companies that demonstrated outstanding performance across all environmental, social, and governance areas. With this result, HK inno.N has ranked No. 1 in its size grade for five consecutive half-year periods since the first half of 2024.
Notably, the 1H 2026 evaluation was the first conducted since HK inno.N joined the group of companies with assets of KRW 2 trillion or more. Outpacing major Korean corporations, the company proved its standing as an ESG-leading firm — a result of significant meaning.
In the environmental area, HK inno.N made visible its greenhouse gas reduction effect from the transition to renewable energy by signing a third-party power purchase agreement (PPA). In the social area, it systematically conducted overseas supply chain due diligence to manage its global supply chain. In the governance area, it established a CEO succession policy to build a transparent and stable management system.
HK inno.N published its '2025 Sustainability Report,' which contains its ESG management strategy and performance, on June 30. The report was fully revamped from the previous horizontal layout to the vertical format, the standard disclosure form. In addition, the company built a company-wide ESG data platform, dramatically enhancing the consistency and reliability of its data.
Kwak Dal-won, CEO of HK inno.N, said, “This is a meaningful result, recognizing our ESG performance not only in the pharmaceutical and bio industry but across all industries,” adding, “We will continue to take the lead in spreading sustainable value across the environmental, social, and governance areas.” | 565 |
| 15 | https://www.inno-n.com/pr/news/view/1/1114?sch_text= | 9 537 |
| 16 | https://www.inno-n.com/pr/news/view/1/1112?sch_text= | 13 313 |
| 17 | https://www.inno-n.com/pr/news/view/1/1110?sch_text= | 872 |
| 18 | https://www.inno-n.com/pr/news/view/1/1103?sch_text= | 1 254 |
| 19 |  +1Sin texto... | 937 |
| 20 | Dear investors,
Detailed data from the U.S. Phase 3 clinical trials of K-CAB were presented at Digestive Disease Week 2026 from May 4 to May 5, 2026.
The presented clinical data covered both erosive esophagitis (EE) treatment and maintenance therapy. In the treatment of erosive esophagitis, K-CAB demonstrated superiority over PPIs across all patient groups in terms of healing rates. In addition, K-CAB also showed differentiated superiority in maintenance therapy following the healing of erosive esophagitis. Notably, this marks the first case among P-CAB therapies to clearly demonstrate superiority over PPIs. These results provide strong evidence that K-CAB may establish a new treatment paradigm in the gastroesophageal reflux disease (GERD) market.
Please refer to the links and graphs below for further details.
*inno.N's press release : https://www.inno-n.com/pr/news/view/1/1101?sch_text=
*Sebela(U.S. partner)'s press release : https://www.prnewswire.com/news-releases/sebela-pharmaceuticals-presents-phase-3-tegoprazan-data-in-erosive-esophagitis-at-digestive-disease-week-ddw-2026-302762622.html
*Graphs are attached. | 970 |
